RPG Life Sciences acquiring Raghava Life Sciences’ API, intermediates business for ₹135 crore
Source Entity
India Latest News: Top National Headlines Today & Breaking News | The Hindu
RPG Life Sciences is acquiring Raghava Life Sciences’ API and intermediates business for ₹135 crore via a slump sale. This strategic move aims to scale the company's manufacturing capabilities and broaden its product portfolio through its subsidiary, RPG Active Pharma.
Strategic Expansion: RPG Life Sciences Acquires Raghava Life Sciences Business
RPG Life Sciences has officially announced the acquisition of the active pharmaceutical ingredients (API) and intermediates business of Raghava Life Sciences for a total consideration of ₹135 crore. This transaction is structured as a slump sale, executed through a business transfer agreement (BTA) on a going-concern basis. By choosing this route, RPG Life Sciences is acquiring specific business assets rather than the equity shares of the entity itself, allowing for a cleaner integration of operations into their existing framework.
The Role of RPG Active Pharma
The acquisition is being facilitated through RPG Active Pharma, a wholly owned subsidiary of RPG Life Sciences. This move is a critical component of a broader 'buy-and-build' strategy designed to consolidate the company's position within the competitive pharmaceutical manufacturing landscape. By leveraging this subsidiary, the parent company is creating a dedicated, integrated, and scaled organization specifically focused on the API segment, which remains a high-growth area in the global pharmaceutical supply chain.
Strengthening the Manufacturing Footprint
Following the recent acquisition of Actis Generics, this transaction represents the next logical step in RPG Life Sciences' efforts to enhance its manufacturing base. The addition of Raghava Life Sciences' API and intermediates business provides an immediate boost to the company's production capacity. This increased scale is essential for meeting the growing demand for high-quality pharmaceutical building blocks, which are critical for both domestic and international drug manufacturing requirements.
Broadening the Portfolio and Regulatory Capabilities
Beyond mere physical assets, the acquisition is expected to significantly broaden the company’s product portfolio. Integrating new intermediates and API technologies allows RPG Life Sciences to offer a more diverse range of products to its global clientele. Furthermore, this expansion enhances the company's regulatory capabilities, a vital asset in an industry governed by stringent international quality standards and compliance requirements.
Future Outlook and Market Implications
This move signifies a clear trend of consolidation within the Indian pharmaceutical sector, where mid-sized players are increasingly looking to achieve scale through strategic inorganic growth. By securing better customer access and diversifying their manufacturing footprint, RPG Life Sciences is positioning itself to be more resilient against supply chain volatility. Looking ahead, this integrated approach will likely serve as a blueprint for the company as it continues to balance organic growth with targeted acquisitions to maintain its competitive edge in the API market.
Verification Required?